{"id":408321,"date":"2021-01-05T07:33:30","date_gmt":"2021-01-05T12:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408321"},"modified":"2021-01-05T07:33:30","modified_gmt":"2021-01-05T12:33:30","slug":"frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"

<\/p>\n

Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference<\/b><\/p>\n

\n\u00a0Company to Review FX-322 Clinical Development Program, Progress and Upcoming Milestones for the First Potential Medicine to Treat Sensorineural Hearing Loss<\/i><\/b><\/p>\n

WOBURN, Mass.–(BUSINESS WIRE<\/a>)–
\nFrequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body\u2019s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 39th<\/sup> annual J.P. Morgan Healthcare conference.\n<\/p>\n

\nMr. Lucchino\u2019s presentation will take place on Wednesday, January 13th<\/sup> at 7:30 a.m. ET. The presentation will be followed by a question and answer session to be held at 8:00 a.m. ET. A live webcast of both the presentation and the breakout session can be accessed on the investors section of Frequency\u2019s website, investors.frequencytx.com<\/a>. A replay of the presentation will be posted on the Frequency website following the event.\n<\/p>\n

About Frequency Therapeutics<\/b><\/p>\n

\nFrequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company\u2019s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company\u2019s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1\/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. FX-322 is being evaluated in multiple ongoing clinical studies in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including in a pre-clinical program in multiple sclerosis.\n<\/p>\n

\nHeadquartered in Woburn, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Massachusetts Eye and Ear, Cambridge Enterprises Limited, Mass General Brigham and the Massachusetts Institute of Technology. For more information, visit www.frequencytx.com<\/a> and follow Frequency on Twitter @Frequencytx.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210105005110\/en\/<\/a><\/span><\/p>\n

\nInvestor:
\n
Carlo Tanzi, Ph.D.
\n
Kendall Investor Relations
\n
ctanzi@kendallir.com
\n<\/a>
617-914-0008<\/p>\n

Media:
\n
Suzanne Day
\n
Frequency Therapeutics
\n
Tel: 781-496-2211
\n
Email: sday@frequencytx.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Stem Cells Clinical Trials General Health Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference \u00a0Company to Review FX-322 Clinical Development Program, Progress and Upcoming Milestones for the First Potential Medicine to Treat Sensorineural Hearing Loss WOBURN, Mass.–(BUSINESS WIRE)– Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body\u2019s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 39th annual J.P. Morgan Healthcare conference. Mr. Lucchino\u2019s presentation will take place on Wednesday, January 13th at 7:30 a.m. ET. The presentation will be followed by a question and answer session to be held … <\/p>\n

Continue reading “Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408321","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFrequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference \u00a0Company to Review FX-322 Clinical Development Program, Progress and Upcoming Milestones for the First Potential Medicine to Treat Sensorineural Hearing Loss WOBURN, Mass.–(BUSINESS WIRE)– Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body\u2019s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 39th annual J.P. Morgan Healthcare conference. Mr. Lucchino\u2019s presentation will take place on Wednesday, January 13th at 7:30 a.m. ET. The presentation will be followed by a question and answer session to be held … Continue reading "Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T12:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-05T12:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":439,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-05T12:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference \u00a0Company to Review FX-322 Clinical Development Program, Progress and Upcoming Milestones for the First Potential Medicine to Treat Sensorineural Hearing Loss WOBURN, Mass.–(BUSINESS WIRE)– Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body\u2019s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 39th annual J.P. Morgan Healthcare conference. Mr. Lucchino\u2019s presentation will take place on Wednesday, January 13th at 7:30 a.m. ET. The presentation will be followed by a question and answer session to be held … Continue reading \"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T12:33:30+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2021-01-05T12:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":439,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/","name":"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-05T12:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005110r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/frequency-therapeutics-to-present-2021-business-and-pipeline-overview-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408321"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408321\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}